SK16352000A3 - Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny - Google Patents
Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny Download PDFInfo
- Publication number
- SK16352000A3 SK16352000A3 SK1635-2000A SK16352000A SK16352000A3 SK 16352000 A3 SK16352000 A3 SK 16352000A3 SK 16352000 A SK16352000 A SK 16352000A SK 16352000 A3 SK16352000 A3 SK 16352000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- indolyl
- formula
- methanone
- dihydro
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 4
- 150000001875 compounds Chemical class 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 3
- -1 acyclic primary amine Chemical class 0.000 claims description 110
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 150000003254 radicals Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 150000005840 aryl radicals Chemical class 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- QTIQVLAVCXXZPS-UHFFFAOYSA-N 1h-indol-2-yl-(5-methoxy-1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3NC4=CC=C(C=C4C=3)OC)=CC2=C1 QTIQVLAVCXXZPS-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical class *N=[N+]=[N-] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 230000003211 malignant effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229910004298 SiO 2 Inorganic materials 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 238000000354 decomposition reaction Methods 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 108091008606 PDGF receptors Proteins 0.000 description 11
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- AALNCHNFTKRFEL-UHFFFAOYSA-N (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3NC4=CC=C(C=C4C=3)O)=CC2=C1 AALNCHNFTKRFEL-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- XBOHHIKJBLNYNQ-UHFFFAOYSA-N 4-(phenylmethoxymethyl)-4,14,18-triazahexacyclo[15.7.0.02,6.07,15.08,13.019,24]tetracosa-1(17),2(6),7(15),8,10,12,19,21,23-nonaene-3,5-dione Chemical compound O=C1C(C=2C3=CC=CC=C3NC=2CC2=C3C4=CC=CC=C4N2)=C3C(=O)N1COCC1=CC=CC=C1 XBOHHIKJBLNYNQ-UHFFFAOYSA-N 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HYJTUULYIOBNLS-UHFFFAOYSA-N bis(1h-indol-3-yl)methanone Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 HYJTUULYIOBNLS-UHFFFAOYSA-N 0.000 description 2
- INQULSKYFIYGGB-UHFFFAOYSA-N bis[1-(benzenesulfonyl)indol-2-yl]methanone Chemical compound C=1C2=CC=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1C(=O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 INQULSKYFIYGGB-UHFFFAOYSA-N 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- CZSDOEWXPKHDJI-UHFFFAOYSA-N 1,2,3,8,9,10-hexahydroindolo[3',2':5,6]pyrrolo-[3',4':3,4]cyclohepta[b]indole-1,3-dione Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C1N1)=C1CC1=C2C2=CC=CC=C2N1 CZSDOEWXPKHDJI-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- AZFYAXFJYYDSLY-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-[2-[1-(benzenesulfonyl)indol-2-yl]ethenyl]indole Chemical compound C=1C2=CC=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1C=CC1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 AZFYAXFJYYDSLY-UHFFFAOYSA-N 0.000 description 1
- SLGHOIGGIHLLBR-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-[[1-(benzenesulfonyl)-5-methoxyindol-2-yl]-phenylmethoxymethyl]-5-methoxyindole Chemical compound C=1C2=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1C(C=1N(C2=CC=C(OC)C=C2C=1)S(=O)(=O)C=1C=CC=CC=1)OCC1=CC=CC=C1 SLGHOIGGIHLLBR-UHFFFAOYSA-N 0.000 description 1
- MEKUBKYBNPQWDE-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-[[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methyl]-7-methoxyindole Chemical compound C=1C2=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1CC1=CC2=CC=CC(OC)=C2N1S(=O)(=O)C1=CC=CC=C1 MEKUBKYBNPQWDE-UHFFFAOYSA-N 0.000 description 1
- XJRMGHHVPRHFAZ-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-[[1-(benzenesulfonyl)indol-2-yl]methyl]-5-methoxyindole Chemical compound C=1C2=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1CC1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 XJRMGHHVPRHFAZ-UHFFFAOYSA-N 0.000 description 1
- AADXUWLNQKNVLR-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-[[1-(benzenesulfonyl)indol-2-yl]methyl]indole Chemical compound C=1C2=CC=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1CC1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 AADXUWLNQKNVLR-UHFFFAOYSA-N 0.000 description 1
- VDWLCYCWLIKWBV-UHFFFAOYSA-N 1-(benzenesulfonyl)indole Chemical compound C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 VDWLCYCWLIKWBV-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- NWOGAKOZPSQOCY-ALILXCBGSA-N 14-[(2R,3R,4R,5R,6R)-3-hydroxy-4,5-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]-4-(phenylmethoxymethyl)-4,14,18-triazahexacyclo[15.7.0.02,6.07,15.08,13.019,24]tetracosa-1(17),2(6),7(15),8,10,12,19,21,23-nonaene-3,5-dione Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1OCC1=CC=CC=C1)COCC1=CC=CC=C1)N1C2=C(C3=CC=CC=C13)C1=C(C3=C(C2)NC=2C=CC=CC=23)C(N(C1=O)COCC1=CC=CC=C1)=O)O NWOGAKOZPSQOCY-ALILXCBGSA-N 0.000 description 1
- NWOGAKOZPSQOCY-PKGQXOGMSA-N 14-[(3R,4R,5R,6R)-3-hydroxy-4,5-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]-4-(phenylmethoxymethyl)-4,14,18-triazahexacyclo[15.7.0.02,6.07,15.08,13.019,24]tetracosa-1(17),2(6),7(15),8,10,12,19,21,23-nonaene-3,5-dione Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H](C(O[C@@H]([C@H]1OCC1=CC=CC=C1)COCC1=CC=CC=C1)N1C2=C(C3=CC=CC=C13)C1=C(C3=C(C2)NC=2C=CC=CC=23)C(N(C1=O)COCC1=CC=CC=C1)=O)O NWOGAKOZPSQOCY-PKGQXOGMSA-N 0.000 description 1
- XOXXUQMBOKKTMI-UHFFFAOYSA-N 1h-indol-2-yl-(5-phenylmethoxy-1h-indol-2-yl)methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)C(NC1=CC=2)=CC1=CC=2OCC1=CC=CC=C1 XOXXUQMBOKKTMI-UHFFFAOYSA-N 0.000 description 1
- DWYWLCSGQIEHHB-UHFFFAOYSA-N 1h-indol-2-yl-[5-(4-iodobutoxy)-1h-indol-2-yl]methanone Chemical compound C1=CC=C2NC(C(=O)C=3NC4=CC=C(C=C4C=3)OCCCCI)=CC2=C1 DWYWLCSGQIEHHB-UHFFFAOYSA-N 0.000 description 1
- BPNCVKJYVNNMJL-UHFFFAOYSA-N 1h-indol-2-yl-[5-(5-iodopentoxy)-1h-indol-2-yl]methanone Chemical compound C1=CC=C2NC(C(=O)C=3NC4=CC=C(C=C4C=3)OCCCCCI)=CC2=C1 BPNCVKJYVNNMJL-UHFFFAOYSA-N 0.000 description 1
- SBNOTUDDIXOFSN-UHFFFAOYSA-N 1h-indole-2-carbaldehyde Chemical compound C1=CC=C2NC(C=O)=CC2=C1 SBNOTUDDIXOFSN-UHFFFAOYSA-N 0.000 description 1
- OBQMSVPFIAYPQJ-UHFFFAOYSA-N 2-(1h-indol-2-ylmethyl)-5-methoxy-1h-indole Chemical compound C1=CC=C2NC(CC=3NC4=CC=C(C=C4C=3)OC)=CC2=C1 OBQMSVPFIAYPQJ-UHFFFAOYSA-N 0.000 description 1
- PZRDOFVRESQTIF-UHFFFAOYSA-N 2-[3-(1h-indol-2-yl)propyl]-1h-indole Chemical compound C1=CC=C2NC(CCCC=3NC4=CC=CC=C4C=3)=CC2=C1 PZRDOFVRESQTIF-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylamino-1-chloro-ethane hydrochloride Natural products CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BWNBLGQCCSCCHF-UHFFFAOYSA-N 2-ethyl-1h-indole Chemical compound C1=CC=C2NC(CC)=CC2=C1 BWNBLGQCCSCCHF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- ZXTNTJHOHDWCOS-UHFFFAOYSA-N 3-bromo-4-[2-[4-(1h-indol-2-yl)butyl]-1h-indol-3-yl]-1-methylpyrrole-2,5-dione Chemical compound O=C1N(C)C(=O)C(Br)=C1C(C1=CC=CC=C1N1)=C1CCCCC1=CC2=CC=CC=C2N1 ZXTNTJHOHDWCOS-UHFFFAOYSA-N 0.000 description 1
- MSWUKAGKHYTDAP-UHFFFAOYSA-N 3-bromo-4-[2-[8-[3-(4-bromo-1-methyl-2,5-dioxopyrrol-3-yl)-1h-indol-2-yl]octyl]-1h-indol-3-yl]-1-methylpyrrole-2,5-dione Chemical compound O=C1N(C)C(=O)C(Br)=C1C(C1=CC=CC=C1N1)=C1CCCCCCCCC1=C(C=2C(N(C)C(=O)C=2Br)=O)C2=CC=CC=C2N1 MSWUKAGKHYTDAP-UHFFFAOYSA-N 0.000 description 1
- CDYQAKWHBKYDBN-UHFFFAOYSA-N 3-bromo-4-[2-[8-[3-(4-bromo-2,5-dioxopyrrol-3-yl)-1h-indol-2-yl]octyl]-1h-indol-3-yl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(Br)=C1C(C1=CC=CC=C1N1)=C1CCCCCCCCC1=C(C=2C(NC(=O)C=2Br)=O)C2=CC=CC=C2N1 CDYQAKWHBKYDBN-UHFFFAOYSA-N 0.000 description 1
- SJJRGLWQVMZVMB-UHFFFAOYSA-N 4,11-diazatetracyclo[8.7.0.02,6.012,17]heptadeca-1,6,8,10,12,14,16-heptaene-3,5-dione Chemical compound C1(NC(C=2C1=C1C(=NC=3C=CC=CC1=3)C=CC=2)=O)=O SJJRGLWQVMZVMB-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- SMGCZMDWKLUIHX-UHFFFAOYSA-N 4-methyl-4,14,18-triazahexacyclo[15.7.0.02,6.07,15.08,13.019,24]tetracosa-1(17),2(6),7(15),8,10,12,19,21,23-nonaene-3,5-dione Chemical compound O=C1N(C)C(=O)C2=C1C(C1=CC=CC=C1N1)=C1CC1=C2C2=CC=CC=C2N1 SMGCZMDWKLUIHX-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NTJAFMGDEWWZKI-UHFFFAOYSA-N C1(NC(C2=C1C=CC=C1C=CC=C3C=CNC132)=O)=O Chemical compound C1(NC(C2=C1C=CC=C1C=CC=C3C=CNC132)=O)=O NTJAFMGDEWWZKI-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- VQCWHJWXZGWNND-UHFFFAOYSA-N O=C1C=CC(=O)N1C1=CC2=CC=CC=C2N1 Chemical compound O=C1C=CC(=O)N1C1=CC2=CC=CC=C2N1 VQCWHJWXZGWNND-UHFFFAOYSA-N 0.000 description 1
- MGTUTWSUKUWJSB-UHFFFAOYSA-N O=C1CC(=O)c2c3C=CC=CC=c3[nH]c2=C1 Chemical compound O=C1CC(=O)c2c3C=CC=CC=c3[nH]c2=C1 MGTUTWSUKUWJSB-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- OWPIWMHSYFCTGY-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-[(dimethylamino)methyl]indol-2-yl]-[1-(benzenesulfonyl)indol-2-yl]methanol Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C2=CC=CC=C2C(CN(C)C)=C1C(O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 OWPIWMHSYFCTGY-UHFFFAOYSA-N 0.000 description 1
- WOCAPKSEBLGEJN-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-2-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound C=1C2=CC(OC)=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1C(=O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 WOCAPKSEBLGEJN-UHFFFAOYSA-N 0.000 description 1
- MJDBPGHWHLCOOO-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-2-yl]-[1-(benzenesulfonyl)-6-methoxyindol-2-yl]methanol Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C2=CC(OC)=CC=C2C=C1C(O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 MJDBPGHWHLCOOO-UHFFFAOYSA-N 0.000 description 1
- HKQIKNJIRUQKAP-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-2-yl]-[1-(benzenesulfonyl)-7-methoxyindol-2-yl]methanol Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C=2C(OC)=CC=CC=2C=C1C(O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 HKQIKNJIRUQKAP-UHFFFAOYSA-N 0.000 description 1
- WJMRAOOEWCYNPT-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-2-yl]-[1-(benzenesulfonyl)-7-methoxyindol-2-yl]methanone Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C=2C(OC)=CC=CC=2C=C1C(=O)C1=CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 WJMRAOOEWCYNPT-UHFFFAOYSA-N 0.000 description 1
- HRNOZQIWUKARCY-UHFFFAOYSA-N [5-(cyclohexylmethoxy)-1h-indol-2-yl]-(1h-indol-2-yl)methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)C(NC1=CC=2)=CC1=CC=2OCC1CCCCC1 HRNOZQIWUKARCY-UHFFFAOYSA-N 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000417 anti-transforming effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- DAKIDYQCFJQMDF-UHFFFAOYSA-N dichloromethane;pyridine Chemical compound ClCCl.C1=CC=NC=C1 DAKIDYQCFJQMDF-UHFFFAOYSA-N 0.000 description 1
- OUWSNHWQZPEFEX-UHFFFAOYSA-N diethyl glutarate Chemical compound CCOC(=O)CCCC(=O)OCC OUWSNHWQZPEFEX-UHFFFAOYSA-N 0.000 description 1
- TWJAXIHBWPVMIR-UHFFFAOYSA-N diindolylmethane Natural products C1=CC=C2NC(CC=3NC4=CC=CC=C4C=3)=CC2=C1 TWJAXIHBWPVMIR-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- SEEYREPSKCQBBF-UHFFFAOYSA-N n-methylmaleimide Chemical compound CN1C(=O)C=CC1=O SEEYREPSKCQBBF-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000013155 positive regulation of cell migration Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- XEQIIPXYGKVBBB-UHFFFAOYSA-N trimethyl-[2-[(2-tributylstannylindol-1-yl)methoxy]ethyl]silane Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)C([Sn](CCCC)(CCCC)CCCC)=CC2=C1 XEQIIPXYGKVBBB-UHFFFAOYSA-N 0.000 description 1
- AKQNYQDSIDKVJZ-UHFFFAOYSA-N triphenylsilane Chemical compound C1=CC=CC=C1[SiH](C=1C=CC=CC=1)C1=CC=CC=C1 AKQNYQDSIDKVJZ-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19819835 | 1998-05-04 | ||
DE19838506A DE19838506C2 (de) | 1998-05-04 | 1998-08-25 | Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen |
PCT/DE1999/001214 WO1999057117A2 (fr) | 1998-05-04 | 1999-04-22 | Derives indoliques et leur utilisation pour le traitement de maladies malignes et autres induites par des proliferations cellulaires pathologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
SK16352000A3 true SK16352000A3 (sk) | 2002-07-02 |
Family
ID=26045937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1635-2000A SK16352000A3 (sk) | 1998-05-04 | 1999-04-22 | Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny |
Country Status (22)
Country | Link |
---|---|
US (2) | US6407102B1 (fr) |
EP (1) | EP1109785B1 (fr) |
JP (1) | JP2002514572A (fr) |
CN (1) | CN1151127C (fr) |
AT (1) | ATE230394T1 (fr) |
AU (1) | AU752464B2 (fr) |
BG (1) | BG104996A (fr) |
BR (1) | BR9911017A (fr) |
CA (1) | CA2330756C (fr) |
CZ (1) | CZ20003960A3 (fr) |
DE (1) | DE59903921D1 (fr) |
DK (1) | DK1109785T3 (fr) |
ES (1) | ES2190221T3 (fr) |
HK (1) | HK1038354A1 (fr) |
HU (1) | HUP0102563A3 (fr) |
IL (1) | IL139056A0 (fr) |
NO (1) | NO317261B1 (fr) |
NZ (1) | NZ507735A (fr) |
PL (1) | PL346840A1 (fr) |
SK (1) | SK16352000A3 (fr) |
TR (1) | TR200003206T2 (fr) |
WO (1) | WO1999057117A2 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200003206T2 (tr) | 1998-05-04 | 2001-07-23 | Zentaris Ag | İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları. |
US6719520B2 (en) | 1998-10-08 | 2004-04-13 | Smithkline Beecham Corporation | Method and compounds |
EP1119548B1 (fr) * | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione utile comme inhibiteur de glycogen synthase kinase-3 (gsk-3) |
AU2001268051A1 (en) * | 2000-06-28 | 2002-01-08 | Eli Lilly And Company | Spla2 inhibitors |
WO2002010131A1 (fr) * | 2000-07-28 | 2002-02-07 | Sumitomo Pharmaceuticals Co., Ltd. | Derives du pyrrole |
TW557298B (en) * | 2000-08-14 | 2003-10-11 | Ciba Sc Holding Ag | A compound, a photopolymerizible composition, a process for producing coatings and a method for causing a photoinitiator to accumulate at the surface of coatings |
US20030032625A1 (en) * | 2001-03-29 | 2003-02-13 | Topo Target Aps | Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors |
DE10143079A1 (de) * | 2001-09-03 | 2003-05-15 | Zentaris Ag | Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel |
US20050267303A1 (en) * | 2001-09-04 | 2005-12-01 | Zentaris Ag | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals |
EP1479384A1 (fr) * | 2002-01-30 | 2004-11-24 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de fibrose |
US6800655B2 (en) | 2002-08-20 | 2004-10-05 | Sri International | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20050288255A1 (en) * | 2004-05-03 | 2005-12-29 | David Hui | Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
JP2009514893A (ja) * | 2005-11-03 | 2009-04-09 | イリプサ, インコーポレイテッド | 多価インドール化合物およびホスホリパーゼa2インヒビターとしてのその使用 |
MX2008005660A (es) * | 2005-11-03 | 2008-12-15 | Ilypsa Inc | Compuestos de indol que tienen sustituyentes c4-amida y uso de los mismos como inhibidores de la fosfolipasa a2. |
CA2627353A1 (fr) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Composes d'indole presentant des substituants acides c4 et leur utilisation en tant qu'inhibiteurs de phospholipases a2 |
JP2009514892A (ja) * | 2005-11-03 | 2009-04-09 | イリプサ, インコーポレイテッド | 多価ホスホリパーゼインヒビターを含むホスホリパーゼインヒビター、および内腔に局在化されるホスホリパーゼインヒビターとしての使用を含むその使用 |
MX2008005662A (es) * | 2005-11-03 | 2008-12-15 | Ilypsa Inc | Compuestos de azaindol y uso de los mismos como inhibidores de la fosfolipasa a2. |
US20090142832A1 (en) * | 2007-11-29 | 2009-06-04 | James Dalton | Indoles, Derivatives, and Analogs Thereof and Uses Therefor |
TWI490219B (zh) | 2009-06-29 | 2015-07-01 | Incyte Corp | 作為pi3k抑制劑之嘧啶酮 |
CN101704828A (zh) * | 2009-11-04 | 2010-05-12 | 中国科学院昆明植物研究所 | 山橙素类双吲哚化合物,其药物组合物及其制备方法和用途 |
AR079529A1 (es) * | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
EP2558463A1 (fr) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Dérivés condensés en tant qu'inhibiteurs de i3 |
WO2011163195A1 (fr) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (fr) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
TWI543980B (zh) | 2011-09-02 | 2016-08-01 | 英塞特控股公司 | 作為pi3k抑制劑之雜環基胺 |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
LT3831833T (lt) | 2015-02-27 | 2023-02-27 | Incyte Holdings Corporation | Pi3k inhibitoriaus gamybos būdai |
WO2016183060A1 (fr) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
CN106317169B (zh) * | 2015-06-23 | 2019-07-02 | 首都医科大学 | 双吲哚-二肽衍生物,其合成,抗血栓活性和制备抗血栓剂的应用 |
WO2018024172A1 (fr) * | 2016-08-05 | 2018-02-08 | The University Of Hong Kong | Complexes de platine et leurs procédés d'utilisation |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
WO2020245208A1 (fr) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation de cd9 en tant que biomarqueur et en tant que biocible dans la glomérulonéphrite ou la glomérulosclérose |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598583A (en) * | 1968-08-09 | 1971-08-10 | Itek Corp | Indomethylene dye bases and their utilization in photographic processes and compositions |
FR2688220A1 (fr) * | 1992-03-06 | 1993-09-10 | Adir | Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO1994024117A1 (fr) * | 1993-04-22 | 1994-10-27 | Nippon Shinyaku Co., Ltd. | Derive de l'acide benzofurancarboxylique et composition pharmaceutique |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
PT817627E (pt) * | 1993-12-23 | 2005-07-29 | Lilly Co Eli | Inibidores da proteina cinase c |
JPH08295688A (ja) * | 1995-04-28 | 1996-11-12 | Sharp Corp | ビスアゾ化合物、その中間体及びそれらの製造方法、並びにビスアゾ化合物を含有する電子写真感光体 |
DE19547263C2 (de) * | 1995-12-07 | 1999-04-29 | Cardiotec Inc | Amidinohydrazone vom Benzo[b]furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
TR200003206T2 (tr) | 1998-05-04 | 2001-07-23 | Zentaris Ag | İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları. |
-
1999
- 1999-04-22 TR TR2000/03206T patent/TR200003206T2/xx unknown
- 1999-04-22 SK SK1635-2000A patent/SK16352000A3/sk unknown
- 1999-04-22 IL IL13905699A patent/IL139056A0/xx not_active IP Right Cessation
- 1999-04-22 PL PL99346840A patent/PL346840A1/xx not_active Application Discontinuation
- 1999-04-22 HU HU0102563A patent/HUP0102563A3/hu unknown
- 1999-04-22 WO PCT/DE1999/001214 patent/WO1999057117A2/fr not_active Application Discontinuation
- 1999-04-22 BR BR9911017-2A patent/BR9911017A/pt not_active IP Right Cessation
- 1999-04-22 CA CA002330756A patent/CA2330756C/fr not_active Expired - Fee Related
- 1999-04-22 ES ES99927711T patent/ES2190221T3/es not_active Expired - Lifetime
- 1999-04-22 CZ CZ20003960A patent/CZ20003960A3/cs unknown
- 1999-04-22 EP EP99927711A patent/EP1109785B1/fr not_active Expired - Lifetime
- 1999-04-22 AT AT99927711T patent/ATE230394T1/de not_active IP Right Cessation
- 1999-04-22 AU AU44975/99A patent/AU752464B2/en not_active Ceased
- 1999-04-22 JP JP2000547087A patent/JP2002514572A/ja not_active Withdrawn
- 1999-04-22 DK DK99927711T patent/DK1109785T3/da active
- 1999-04-22 DE DE59903921T patent/DE59903921D1/de not_active Expired - Fee Related
- 1999-04-22 CN CNB998058033A patent/CN1151127C/zh not_active Expired - Fee Related
- 1999-05-04 US US09/305,115 patent/US6407102B1/en not_active Expired - Fee Related
-
2000
- 2000-10-24 NZ NZ507735A patent/NZ507735A/xx unknown
- 2000-10-27 NO NO20005448A patent/NO317261B1/no unknown
- 2000-11-28 BG BG104996A patent/BG104996A/xx unknown
-
2001
- 2001-12-27 HK HK01109122A patent/HK1038354A1/xx not_active IP Right Cessation
-
2002
- 2002-05-03 US US10/137,653 patent/US6812243B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1151127C (zh) | 2004-05-26 |
NO20005448D0 (no) | 2000-10-27 |
IL139056A0 (en) | 2001-11-25 |
US6812243B2 (en) | 2004-11-02 |
US6407102B1 (en) | 2002-06-18 |
JP2002514572A (ja) | 2002-05-21 |
TR200003206T2 (tr) | 2001-07-23 |
ES2190221T3 (es) | 2003-07-16 |
ATE230394T1 (de) | 2003-01-15 |
BG104996A (en) | 2001-07-31 |
BR9911017A (pt) | 2001-02-06 |
US20030008898A1 (en) | 2003-01-09 |
WO1999057117A2 (fr) | 1999-11-11 |
AU4497599A (en) | 1999-11-23 |
NZ507735A (en) | 2003-04-29 |
HUP0102563A2 (hu) | 2001-11-28 |
HK1038354A1 (en) | 2002-03-15 |
NO20005448L (no) | 2000-10-27 |
WO1999057117A3 (fr) | 2001-04-12 |
PL346840A1 (en) | 2002-02-25 |
NO317261B1 (no) | 2004-09-27 |
CN1310705A (zh) | 2001-08-29 |
CA2330756A1 (fr) | 1999-11-11 |
EP1109785A2 (fr) | 2001-06-27 |
CA2330756C (fr) | 2007-10-02 |
AU752464B2 (en) | 2002-09-19 |
EP1109785B1 (fr) | 2003-01-02 |
CZ20003960A3 (cs) | 2002-04-17 |
HUP0102563A3 (en) | 2003-04-28 |
DK1109785T3 (da) | 2003-04-22 |
DE59903921D1 (de) | 2003-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK16352000A3 (sk) | Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny | |
FI96861B (fi) | Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi | |
AU2005202387B2 (en) | Indolylmaleimide derivatives as protein kinase C inhibitors | |
WO2002096361A2 (fr) | Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase | |
JP6268276B2 (ja) | PERK阻害剤としての新規なN(2,3−ジヒドロ−1H−ピロロ[2,3−b]ピリジン−5−イル)−4−キナゾリンアミン誘導体およびN−(2,3−ジヒドロ−1H−インドール−5−イル)−4−キナゾリンアミン誘導体 | |
KR20080087851A (ko) | 신규한 시클릭 우레아 유도체, 그의 제조법 및 키나제억제제로서의 그의 제약 용도 | |
JP2018528193A (ja) | インドール誘導体、その調製方法および医薬におけるその使用 | |
US20040053949A1 (en) | Indolylmaleimide derivatives | |
JP2019520412A (ja) | 哺乳動物のチロシンキナーゼror1活性の阻害剤として有用な2−フェニルイミダゾ[4,5−b]ピリジン−7−アミン誘導体 | |
USRE36736E (en) | Substituted pyrroles | |
KR20110082094A (ko) | 6-시클로아미노-3-(1h-피롤로[2,3-b]피리딘-4-일)이미다조[1,2-b]피리다진 유도체, 그의 제법 및 그의 치료적 용도 | |
MXPA02006162A (es) | Pirroles sustituidos. | |
WO2020173328A1 (fr) | Dérivé de pyrrole et son procédé de préparation et son application | |
KR20010043288A (ko) | 인돌 유도체 및 병리학적 세포 증식으로 인한 악성 질환과기타 질환의 치료에 있어서 이의 용도 | |
RU1799382C (ru) | Способ получени замещенных пирролов или их фармацевтически приемлемых солей | |
MXPA00010739A (en) | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation | |
CA2496859A1 (fr) | Derives indoliques et leur utilisation pour le traitement de maladies malignes et autres induites par des proliferations cellulaires pathologiques |